Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections

Nurse Pract. 2018 Oct;43(10):31-37. doi: 10.1097/01.NPR.0000544995.21102.7f.


Acute bacterial skin and skin structure infections (ABSSSIs) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSIs are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, the two newest lipoglycopeptides, in the context of the other available I.V. infusion standard therapy options.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Humans
  • Lipoglycopeptides / pharmacology
  • Lipoglycopeptides / therapeutic use*
  • Skin Diseases, Bacterial / drug therapy*
  • Skin Diseases, Bacterial / epidemiology
  • Teicoplanin / analogs & derivatives*
  • Teicoplanin / pharmacology
  • Teicoplanin / therapeutic use


  • Anti-Bacterial Agents
  • Lipoglycopeptides
  • Teicoplanin
  • dalbavancin
  • oritavancin